Preimplantation Genetic Testing Market - Forecasts from 2024 to 2029

The preimplantation genetic testing market is estimated to grow at a CAGR of 10.26% during the forecast period.

Preimplantation genetic diagnosis (PGD) is implemented before IVF workflow. For women who have had several miscarriages and last pregnancy with chromosome abnormality have PGD deployed in IVF cycles. Couples who are at risk of hereditary disorders can benefit from preimplantation genetic testing.

Driving factors for the preimplantation genetic testing market

The major factor influencing the growth of the preimplantation genetic treatment industry is the growing frequency of infertility among individuals and rising genetic problems. Preimplantation genetic testing is growing in demand as it detects defective embryos and has some genetic disorders and other faults that lead to the child being born with health defects. Individuals who have single gene donors, sex-linked genetic disorders, chromosomal problems, or have a history of multiple abortions are increasingly using preimplantation genetic testing methods.

Growing prevalence of neo-natal deaths

Many genetic deformities cause newborn deaths around the globe and hence will propel the growth of the preimplantation genetic treatment market. For instance, according to UNICEF, 6,400 newborns died every day in 2021. Furthermore, there were 18 deaths per thousand live births worldwide making the first month the most dangerous for newborns. Preimplantation genetic diagnosis helps in curbing this issue as it detects defective chromosomes at an early stage and prevents congenital genetic deformities in the fetuses. As the women's age for childbearing increases so is the use of preimplantation genetic testing.

Rising adoption of polymerase chain reaction

Polymerase chain reaction is anticipated to hold the maximum market share during the forecast period owing to the high market penetration and rising cost-effectiveness with high accuracy of PCR tests are fueling the preimplantation genetic treatment industry share. The polymerase chain reaction increases the chance of detection of any chromosomal abnormalities with a large number of copies of a particular stretch of the genome. This technology is suitable for all types of genetic diagnosis.

Growing prevalence of preimplantation genetic diagnosis

The major factor driving the growth of the preimplantation genetic treatment market is the growing awareness among healthcare professionals and consumers about genetic testing. The rising incidence of single gene disease and translocation cases led to the effective delivery of NGS technology for genetic testing. The preimplantation genetic diagnosis (PGD) services help reduce the incidences of genetic diseases which is done by embryo examination to determine specific gene mutations. The PGS services are also gaining popularity as they are suggested for couples with multiple IVF cycles, advanced age, and recurrent pregnancy loss.

Advancements in medical technologies

The growing demand for improved medical services and increasing income is fueling opportunities for the development of advanced diagnostic and treatment approaches. As the need to prevent physical abnormalities and health problems has increased the preimplantation genetic treatment market has seen growth for early diagnostic approaches. These early diagnostic approaches are being used during genetic invitro fertilization and other artificial insemination procedures. Preimplantation genetic testing methods can detect inherited disorders including congenital hearing loss, cystic fibrosis, and many more.

Adoption of next-generation sequencing technology

Next-generation sequencing drives the preimplantation genetic treatment industry due to its high accuracy, efficiency, and comprehensive genetic information. The next-generation sequencing method provides detailed genetic analysis which results in improved success rates of assisted reproductive techniques. Moreover, the adoption of florescent in-situ hybridization is also significantly impacting the preimplantation genetic treatment market due to the growing need to detect chromosomal abnormalities in embryos before implantation. FISH offers rapid results and screens a limited number of chromosomes at a time.

IVF Prognosis is anticipated to hold a significant market share

Preimplantation genetic testing plays an important role in IVF prognosis as it is necessary to inspect the medical condition of the embryos, thereby contributing to the growth of IVF prognosis. The high demand for invitro fertilization procedures is increasing the demand for preimplantation genetic testing procedures in the market. Additionally, many product launches by major market players are further fueling the preimplantation genetic treatment market growth. Rising infertility and increasing preference for IVF procedures are expected to drive the growth of the preimplantation genetic treatment market during the forecast period.

In Europe, it is projected that the preimplantation genetic testing market will grow steadily.

The European region is anticipated to secure a sizable preimplantation genetic treatment market share. The regional preimplantation genetic treatment market will be fueled by the increasing prevalence of late pregnancies. Additionally, the growing liberal regulations in various countries in Europe for screening and the presence of leading market players are fueling the regional preimplantation genetic treatment industry. Furthermore, Asia Pacific is anticipated to grow significantly during the forecast period due to advancements in reproductive health. High adoption of IVF and increasing consumer awareness are further fueling the preimplantation genetic treatment market growth.

Market Key Developments

• In April 2023, The HelpCureHD Foundation and Prelude Network launched the More Than Fertility campaign to increase and educate awareness about IVF with Preimplantation Genetic Testing.
• In October 2022, Genomic Prediction and HelpCureHD collaborated to help partners with the risk of Huntington's disease screen through preimplantation genetic testing.
• In October 2022, Ovation Fertility and Genomic Prediction partners to license the LifeView PGT platform.
• In July 2022, To screen genetic diseases in IVF embryos, GenEmbryomics launched research using genome sequencing tests.

Segmentation:

By Technology

• Next Generation Sequencing
• Polymerase Chain Reaction
• Fluorescent In-Situ Hybridization
• Comparative Genomic Hybridization
• Single Molecule Polymorphism

By Procedure Type

• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis

By Application

• Aneuploidy
• Single Gene Disorders
• X-linked Disorders
• Others

By End-User

• Maternity Clinics
• Hospitals
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others